CoChat

Metabolic alterations mediated by STAT3 promotes drug persistence in CML

Open access

The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.

Abstract

Leukemic stem cells (LSCs) can acquire non-mutational resistance following drug treatment leading to therapeutic failure and relapse. However, oncogene-independent mechanisms of drug persistence in LSCs are incompletely understood, which is the primary focus of this study. We integrated proteomics, transcriptomics, and metabolomics to determine the contribution of STAT3 in promoting metabolic changes in tyrosine kinase inhibitor (TKI) persistent chronic myeloid leukemia (CML) cells. Proteomic and transcriptional differences in TKI persistent CML cells revealed BCR-ABL-independent STAT3 activation in these cells. While knockout of STAT3 inhibited the CML cells from developing drug-persistence, inhibition of STAT3 using a small molecule inhibitor sensitized the persistent CML cells to TKI treatment. Interestingly, given the role of phosphorylated STAT3 as a transcription factor, it localized uniquely to genes regulating metabolic pathways in the TKI-persistent CML stem and progenitor cells. Subsequently, we observed that STAT3 dysregulated mitochondrial metabolism forcing the TKI-persistent CML cells to depend on glycolysis, unlike TKI-sensitive CML cells, which are more reliant on oxidative phosphorylation. Finally, targeting pyruvate kinase M2, a rate-limiting glycolytic enzyme, specifically eradicated the TKI-persistent CML cells. By exploring the role of STAT3 in altering metabolism, we provide critical insight into identifying potential therapeutic targets for eliminating TKI-persistent LSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-021-01315-0

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TKI-persistent CML LSCs and K562s have a distinct transcriptional and proteomic signature. A Representative FACS plot (left) and scatter plot (right) for frequency of HSC/LSC (LSK Flt3−CD48−CD150+) off the stem and progenitor (LSK Flt3−) cells in the BM of CML, CML mice treated with imatinib (200 mg/kg) for 4 weeks and their respective controls. n = 5. B Venn diagram (top) and KEGG pathway analysis (bottom) for common genes upregulated in LSCs obtained from CML mice and CML mice treated with imatinib (200 mg/kg) for 4 weeks and sensitive and IM-persistent K562 cells, obtained from RNA-seq. C Heatmap depicting differentially expressed protein in sensitive and persistent K562 with a fold change >1.4 and p value ≥ 0.01 when assayed by Reverse Phase Protein Array (RPPA). D Representative confocal imaging of (HSC/LSC (Lin−cKit+Sca1+Flt3−CD150+CD48−) for pSTAT3-Y705 (Green) and nucleus (Blue). Frequency of cells having stat3 expression is shown in the table to the right. The transcriptomic and proteomic data was carried out in triplicates. For scatter plot, two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.
Fig. 1 TKI-persistent CML LSCs and K562s have a distinct transcriptional and proteomic signature. A Representative FACS plot (left) and scatter plot (right) for frequency of HSC/LSC (LSK Flt3−CD48−CD150+) off the stem and progenitor (LSK Flt3−) cells in the BM of CML, CML mice treated with imatinib (200 mg/kg) for 4 weeks and their respective controls. n = 5. B Venn diagram (top) and KEGG pathway analysis (bottom) for common genes upregulated in LSCs obtained from CML mice and CML mice treated with imatinib (200 mg/kg) for 4 weeks and sensitive and IM-persistent K562 cells, obtained from RNA-seq. C Heatmap depicting differentially expressed protein in sensitive and persistent K562 with a fold change >1.4 and p value ≥ 0.01 when assayed by Reverse Phase Protein Array (RPPA). D Representative confocal imaging of (HSC/LSC (Lin−cKit+Sca1+Flt3−CD150+CD48−) for pSTAT3-Y705 (Green) and nucleus (Blue). Frequency of cells having stat3 expression is shown in the table to the right. The transcriptomic and proteomic data was carried out in triplicates. For scatter plot, two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.CC BY · PubMed Central
Fig. 2 Active STAT3 is essential for survival and leukemic potential of TKI-persistent CML LSCs. A The sensitive and persistent K562 were treated with LLL12 (1 μM) for 3 days. Treatment was switched to either imatinib (1 μM) or continued with LLL12 (1 μM) for additional 3 days. Cells were analyzed for AnnexinV by flow cytometry. B Dose curve of imatinib for the sensitive and persistent K562 untreated or treated with LLL12 (1 μM) for 3 days. The cells were stained with annexin V and analyzed by flow cytometry. C HSC or LSC count per 10 million BM cells (left), percent AnnexinV stem cells (middle) and 24 hr BrDU incorporation in stem cells (right) of control and CML mice post 4 weeks of imatinib (200 mg/kg) or LLL12 (25 mg/kg) treatment individually or in combination. n = 5. D Survival curves of control and CML mice post 4-week imatinib (200 mg/kg) or LLL12 (25 mg/kg) treatment alone, or in combination. E Limiting dilution CRU (competitive repopulation unit) assay is shown. The indicated numbers of control or leukemic-exposed HSCs were transplanted along with 2 × 105 BM cells of a competitor (CD45.2+) into lethally irradiated hosts (CD45.1+). Reconstitution was evaluated in the blood at 16 weeks post-transplantation (p = 0.0001). Mice with CD45.1+ chimerism <0.3 were considered non-responders. The data is a representative or pool of mean ± SD from two to three independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.
Fig. 2 Active STAT3 is essential for survival and leukemic potential of TKI-persistent CML LSCs. A The sensitive and persistent K562 were treated with LLL12 (1 μM) for 3 days. Treatment was switched to either imatinib (1 μM) or continued with LLL12 (1 μM) for additional 3 days. Cells were analyzed for AnnexinV by flow cytometry. B Dose curve of imatinib for the sensitive and persistent K562 untreated or treated with LLL12 (1 μM) for 3 days. The cells were stained with annexin V and analyzed by flow cytometry. C HSC or LSC count per 10 million BM cells (left), percent AnnexinV stem cells (middle) and 24 hr BrDU incorporation in stem cells (right) of control and CML mice post 4 weeks of imatinib (200 mg/kg) or LLL12 (25 mg/kg) treatment individually or in combination. n = 5. D Survival curves of control and CML mice post 4-week imatinib (200 mg/kg) or LLL12 (25 mg/kg) treatment alone, or in combination. E Limiting dilution CRU (competitive repopulation unit) assay is shown. The indicated numbers of control or leukemic-exposed HSCs were transplanted along with 2 × 105 BM cells of a competitor (CD45.2+) into lethally irradiated hosts (CD45.1+). Reconstitution was evaluated in the blood at 16 weeks post-transplantation (p = 0.0001). Mice with CD45.1+ chimerism <0.3 were considered non-responders. The data is a representative or pool of mean ± SD from two to three independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.CC BY · PubMed Central
Fig. 3 STAT3 localizes to metabolic genes in transcriptionally altered TKI-persistent LSCs. A Kegg GO Pathway analysis depicting z score and p value for the genes differentially bound by pSTAT3-Y705 in the CML and IM-persistent CML LSK. B Heatmap and pathway analysis for integration of the pSTAT3-Y705 bound ChIP-seq peaks and the upregulated RNA-seq genes in the CML and IM-persistent LSK and LSCs respectively. C Ingenuity Pathway analysis bar chart depicting z scores of pathways correlated to overlapping genes of CML vs WT bulk-RNA sequencing and pSTAT3-Y705 ChIP-seq peaks unique to CML as well as overlapping genes of CML-TKI vs WT bulk-RNA sequencing and pSTAT3-Y705 ChIP-seq peaks unique to CML-TKI. D Heatmap and pathway analysis for upregulated genes common between sensitive K562 and IM-persistent K562 treated with 1 μM LLL12 (1 μM) but different from IM-persistent K562. The transcriptomic data were carried out in triplicates.
Fig. 3 STAT3 localizes to metabolic genes in transcriptionally altered TKI-persistent LSCs. A Kegg GO Pathway analysis depicting z score and p value for the genes differentially bound by pSTAT3-Y705 in the CML and IM-persistent CML LSK. B Heatmap and pathway analysis for integration of the pSTAT3-Y705 bound ChIP-seq peaks and the upregulated RNA-seq genes in the CML and IM-persistent LSK and LSCs respectively. C Ingenuity Pathway analysis bar chart depicting z scores of pathways correlated to overlapping genes of CML vs WT bulk-RNA sequencing and pSTAT3-Y705 ChIP-seq peaks unique to CML as well as overlapping genes of CML-TKI vs WT bulk-RNA sequencing and pSTAT3-Y705 ChIP-seq peaks unique to CML-TKI. D Heatmap and pathway analysis for upregulated genes common between sensitive K562 and IM-persistent K562 treated with 1 μM LLL12 (1 μM) but different from IM-persistent K562. The transcriptomic data were carried out in triplicates.CC BY · PubMed Central
Fig. 4 STAT3 contributes to altered metabolism in TKI-persistent CML cells. A ECAR (top) from glycolysis rate assay (GRA) and OCR (bottom) from mitochondrial stress test (MST) of 75,000 sensitive and IM-persistent K562 measured by seahorse. B Heatmap for the top 50 differentially expressed metabolites between IM-persistent K562 and those treated with LLL12 (1 μM) with a p value ≤0.05. Raw values were used to generate the heatmap. C VIP plot for component 1 of the PLS-DA comparing WT HSCs, CML LSCs, IM-persistent CML LSCs. The VIP score indicates the contribution of the metabolite to the clustering pattern. D Scatter plots obtained from integration of the K562 metabolic profile with the K562 RNA-seq data. All figures are mean ± SD of a representative data of at least 2–3 independent experiments. Unpaired student t test. was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.
Fig. 4 STAT3 contributes to altered metabolism in TKI-persistent CML cells. A ECAR (top) from glycolysis rate assay (GRA) and OCR (bottom) from mitochondrial stress test (MST) of 75,000 sensitive and IM-persistent K562 measured by seahorse. B Heatmap for the top 50 differentially expressed metabolites between IM-persistent K562 and those treated with LLL12 (1 μM) with a p value ≤0.05. Raw values were used to generate the heatmap. C VIP plot for component 1 of the PLS-DA comparing WT HSCs, CML LSCs, IM-persistent CML LSCs. The VIP score indicates the contribution of the metabolite to the clustering pattern. D Scatter plots obtained from integration of the K562 metabolic profile with the K562 RNA-seq data. All figures are mean ± SD of a representative data of at least 2–3 independent experiments. Unpaired student t test. was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.CC BY · PubMed Central
Fig. 5 TKI-persistent K562 have an active glycolysis and increased fatty acid accumulation. A Unit area plots for metabolites labeled in glycolysis, citric acid cycle and PPP post 3 h incubation of 200,000 sensitive and IM-persistent K562 with isotopically labeled 13C1,2,3-glucose. The metabolites were measured with UHPLC-MS. B Sensitive and IM-persistent K562 treated with 1 μM Imatinib were starved with glucose (right) or glutamine (middle) for 48 h or treated with 10 μM Etomoxir for 3 days. Cells were analyzed by flow cytometry using annexinV apoptosis assay. The data are representative mean ± SD from two independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.
Fig. 5 TKI-persistent K562 have an active glycolysis and increased fatty acid accumulation. A Unit area plots for metabolites labeled in glycolysis, citric acid cycle and PPP post 3 h incubation of 200,000 sensitive and IM-persistent K562 with isotopically labeled 13C1,2,3-glucose. The metabolites were measured with UHPLC-MS. B Sensitive and IM-persistent K562 treated with 1 μM Imatinib were starved with glucose (right) or glutamine (middle) for 48 h or treated with 10 μM Etomoxir for 3 days. Cells were analyzed by flow cytometry using annexinV apoptosis assay. The data are representative mean ± SD from two independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.CC BY · PubMed Central
Fig. 6 Glycolysis is important for the survival of TKI-persistent CML stem and progenitor cells. A Western blot for PKM2 using sensitive and IM-persistent K562 cell lysate. The bar plot represents density of the persistent protein bands relative to sensitive and normalized to the housekeeping protein, GAPDH. B Sensitive and IM-persistent K562 analyzed for apoptosis via flow cytometry post 3-day treatment with IM (1 μM), LLL12 (1 μM), or Shikonin (0.2 μM) alone, or in combination. C Colony-forming assay for 1000 LSK cells/mL sorted and plated from control, CML, and imatinib (400 mg/kg) treated CML mice. The plates were treated with IM (1 μM) or Shikonin (0.5 μM) alone, or in combination, incubated in hypoxia and colonies counted after 10 days. Data is represented as counts normalized to untreated. D Colony-forming assay for 1000 Lin−CD34+ BM cells/mL sorted and plated from 2 healthy individuals, 5 CML patients at diagnosis and 1 IM treated disease persistent patient. The plates were treated with Imatinib (1 μM) or Shikonin (0.5 μM) alone, or in combination, incubated in hypoxia and colonies counted after 10 days. Data are represented as counts normalized to untreated. The data are representative or a pool of mean ± SD from 2 to 3 independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.
Fig. 6 Glycolysis is important for the survival of TKI-persistent CML stem and progenitor cells. A Western blot for PKM2 using sensitive and IM-persistent K562 cell lysate. The bar plot represents density of the persistent protein bands relative to sensitive and normalized to the housekeeping protein, GAPDH. B Sensitive and IM-persistent K562 analyzed for apoptosis via flow cytometry post 3-day treatment with IM (1 μM), LLL12 (1 μM), or Shikonin (0.2 μM) alone, or in combination. C Colony-forming assay for 1000 LSK cells/mL sorted and plated from control, CML, and imatinib (400 mg/kg) treated CML mice. The plates were treated with IM (1 μM) or Shikonin (0.5 μM) alone, or in combination, incubated in hypoxia and colonies counted after 10 days. Data is represented as counts normalized to untreated. D Colony-forming assay for 1000 Lin−CD34+ BM cells/mL sorted and plated from 2 healthy individuals, 5 CML patients at diagnosis and 1 IM treated disease persistent patient. The plates were treated with Imatinib (1 μM) or Shikonin (0.5 μM) alone, or in combination, incubated in hypoxia and colonies counted after 10 days. Data are represented as counts normalized to untreated. The data are representative or a pool of mean ± SD from 2 to 3 independent experiments. Unpaired student t test or Two-way ANOVA was used to determine statistical significance with Tukey’s multiple comparison. p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns = not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 58

Metadata

Authors
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., Tenen, D. E., Wolock, S. L., Park, J., Ying, L., Yue, Z., Chen, J. Y., Yang, H., Tenen, D. G., Ferrell, P. B., Lu, R., Darley-Usmar, V., D’Alessandro, A., Bhatia, R., & Welner, R. S.
Affiliations
  • University of Alabama at Birmingham (US)
  • University of Colorado Anschutz (US)
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
  • Dicerna Pharmaceuticals (United States) (US)
  • National University of Singapore (SG)
  • Vanderbilt University Medical Center (US)
Corresponding author
Welner, Robert S.
Venue
Leukemia
Published
2021-06-12
Volume
35
Issue
12
Pages
3371-3382
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3171658473
Cited by
56
References
77
Citations by year
2026: 11 · 2025: 10 · 2024: 13 · 2023: 11 · 2022: 8 · 2021: 3
FWCI
6.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Leukemia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion, cc-by)
Funders
  • American Society of Hematology
  • University of Alabama at Birmingham (P30-AI-027767, P30CA013148)
  • University of Alabama (P30 CA013148, P30 AI027767)
  • National Institutes of Health (P30-AI- 027767, P30-CA- 013148, CA013148, AI027767)
  • Center for AIDS Research, University of Washington (CA013148, P30 AI027767, AI027767)
  • National Heart, Lung, and Blood Institute (K23HL138291, P01HL131477)
  • National Cancer Institute (R01CA095684, CA013148, R35CA197697, R01CA248794, P30CA013148)
  • National Institute of Allergy and Infectious Diseases (P30AI027767)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
STAT3, chronic myeloid leukemia, drug resistance, leukemia stem cells, tyrosine kinase inhibitors, mitochondrial metabolism, glycolysis, oxidative phosphorylation, PKM2, metabolic reprogramming, STAT3 inhibitor, relapse
MeSH terms
Animals, Female, Glycolysis, Male, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Apoptosis, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, STAT3 Transcription Factor, Mice, Small Molecule Libraries, Metabolome, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic alterations mediated by STAT3 promotes drug persistence in CML. https://app.cochat.ai/papers/10.1038/s41375-021-01315-0
The paper
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., Tenen, D. E., Wolock, S. L., Park, J., Ying, L., Yue, Z., Chen, J. Y., Yang, H., Tenen, D. G., Ferrell, P. B., . . . Welner, R. S. (2021). Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Leukemia. https://doi.org/10.1038/s41375-021-01315-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.